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The pharmacokinetics of sublingual artemether (ArTiMist) was investigated in 91 young African children with severe malaria or
who could not tolerate oral antimalarial therapy. Each received 3.0 mg/kg of body weight of artemether at 0, 8, 24, 36, 48, and 60
h or until the initiation of oral treatment. Few blood samples were drawn postdose. Plasma artemether and dihydroartemisinin
(DHA) levels were measured using liquid chromatography-mass spectrometry, and the data were analyzed using established
population compartmental pharmacokinetic models. Parasite clearance was prompt (median parasite clearance time, 24 h), and
there were no serious adverse events. Consistent with studies in healthy adults (S. Salman, D. Bendel, T. C. Lee, D. Templeton,
and T. M. E. Davis, Antimicrob Agents Chemother 59:3197–3207, 2015, http://dx.doi.org/10.1128/AAC.05013-14), the absorp-
tion of sublingual artemether was biphasic, and multiple dosing was associated with the autoinduction of the metabolism of
artemether to DHA (which itself has potent antimalarial activity). In contrast to studies using healthy volunteers, pharmacoki-
netic modeling indicated that the first absorption phase did not avoid first-pass metabolism, suggesting that the drug is trans-
ferred to the upper intestine through postdose fluid/food intake. Simulations using the present data and those from an earlier
study in older Melanesian children with uncomplicated malaria treated with artemether-lumefantrine tablets suggested that the
bioavailability of sublingual artemether was at least equivalent to that after conventional oral artemether-lumefantrine (median
[interquartile range] areas under the concentration-time curve for artemether, 3,403 [2,471 to 4,771] versus 3,063 [2,358 to
4,514]g · h/liter, respectively; and for DHA, 2,958 [2,146 to 4,278] versus 2,839 [1,812 to 3,488]g · h/liter, respectively; P>
0.42). These findings suggest that sublingual artemether could be used as prereferral treatment for sick children before transfer
for definitive management of severe or moderately severe malaria.
Although parenteral artesunate is the recommended initialtreatment for severe malaria (1), intramuscular (i.m.) arte-
mether is an acceptable and practical alternative (1, 2). Arte-
mether is also a recommended first-line oral therapy in combina-
tion with the longer half-life partner drug lumefantrine for
uncomplicated Plasmodium falciparum (3) and Plasmodium vivax
(4) infections. There are, however, few detailed studies assessing
the pharmacokinetics of artemether and its active metabolite di-
hydroartemisinin (DHA) in either of these settings in children.
Artemether-lumefantrine is a safe and effective treatment for
uncomplicated pediatric malaria (3, 4), but there is evidence of
significant between-dose variability in absorption even when co-
administeredwith a small amount of fat to improve bioavailability
(5). In addition, the nausea and vomiting that are frequently as-
sociated with malaria, together with an unwell child’s refusal to
feed or take medications by mouth (6), can reduce the effective-
ness of oral treatment through reduced adherence to the World
Health Organization (WHO) recommended 3-day regimen (7).
In cases of more severe malaria, there is evidence of substantial
between-patient variability in the absorption of i.m. artemether
(8, 9), with some acidotic children likely exposed to subtherapeu-
tic concentrations when the recommended doses are given (9).
Rectal artesunate administration is associated with more rapid
absorption and initial parasite clearance than is i.m. artemether
administration in severely ill children (8). However, there is also
marked between-patient variability in the dispositions of artesu-
nate andDHA, and there is evidence that some children are able to
expel artesunate suppositories even in the context of close moni-
toring as part of a formal pharmacokinetic evaluation (10). This
might help explain why artesunate suppositories do not improve
mortality compared to that with a placebo in older relative to
younger pediatric age groups (11).
There is a clear need for a prereferral formulation of an arte-
misinin derivative that can be easily administered and adequately
absorbed in a child who may be unconscious or uncooperative or
in whom nausea and vomiting preclude oral dosing. ArTiMist
(Essential Nutrition Ltd., Brough, England) is an artemether for-
mulation in neutral oil that can be administered as a metered
sublingual spray and which is more rapidly and completely ab-
sorbed than is artemether given in tablet form in healthy adult
volunteers (see accompanying paper [12]). In the present study,
we assessed the pharmacokinetics of ArTiMist in African children
with severe malaria or in whom gastrointestinal symptoms pre-
vented the administration of artemether-lumefantrine tablets.
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MATERIALS AND METHODS
Study site, approvals, and patients. The present study was conducted in
two parts. Study 1 was an open-label randomized comparative trial of an
artemether sublingual spray (ArTiMist; Essential Nutrition Ltd., Brough,
England) and intravenous (i.v.) quinine, whichwas conducted in Rwanda
(Rwinkwavu District Hospital). Study 2 was a phase III, randomized,
open-label, and multicenter superiority trial of ArTiMist versus i.v. qui-
nine, which was carried out at three different sites in Rwanda (Ruhuha
Health Center, Eastern Province), Ghana (Navrongo Health Research
Centre, Upper East Region), and Burkina Faso (Centre National de Re-
cherche et de Formation sur le Paludisme, Ouagadougou). Full details of
trial procedures and the clinical and parasitologic outcomes will be pub-
lished separately. The present data relate only to the pharmacokinetics of
ArTiMist in those children allocated to this form of treatment.
Children weighing between 5 and 15 kg were eligible for either study 1
or 2 if (i) they had falciparum malaria confirmed by blood film micros-
copy showing a P. falciparum density of500 parasites/l of whole blood
(including those positive for other plasmodial species), (ii) they had se-
vere or complicated malaria based on the WHO criteria (13) or uncom-
plicated malaria but were unable to tolerate oral medication as a result of
nausea, vomiting, or diarrhea, (iii) they had received any antimalarial
therapy within the 7 days prior to the first study drug administration, (iv)
they had evidence of significant comorbidity, including other infections,
(v) they had a contraindication or allergy or had a history of intolerance to
either artemether or quinine, and (vi) their parents or attendant relatives/
guardians gave witnessed informed consent and, where possible, the child
assented to participate.
Studies 1 and 2 were approved by the University Teaching Hospital
Kigali Research Ethics Committee (EC/CHUK/002/09 and EC/CHUK/
015/10, respectively, and study 2 was also approved by the Navrongo
Health Research Centre institutional review board (NHRCIRB107) and
Centre National de Recherche et de Formation sur le Paludisme Comité
Institutionnel de Bioéthique (AEP-002/02/2011/CIB-CNRFP). During
the course of study 2, the treatment recommendations for severe child-
hood malaria were updated (1) following the publication of a large ran-
domized controlled trial showing a significant mortality benefit with i.v.
artesunate compared to that with i.v. quinine (14). With the approval of
each ethics committee, local regulatory authorities, and investigators, i.v.
quinine was retained as the comparator regimen since (i) i.v. quinine
remains an acceptable alternative treatment in the updated WHO treat-
ment guidelines (1), and (ii) i.v. artesunate was neither on national treat-
ment guidelines nor available in a good manufacturing practice formula-
tion in any country involved in the present studies at the time.
Study procedures. In study 1, children were randomized by a com-
puter-generated schedule to receive either ArTiMist or i.v. quinine.
ArTiMist was administered at a dose of 3.0 mg/kg of body weight to the
nearest 3.0 mg using the most appropriate combination of 3.0-mg/actu-
ation and 6-mg/actuation delivery devices (which have equivalent bio-
availabilities in adult volunteer studies [11]) at 0, 8, 24, 36, 48, and 60 h or
until the initiation of oral antimalarial therapy. The exact timing of each
dose was recorded. Venous blood samples (5 ml) were collected via direct
venipuncture under a sparse sampling protocol. The first sample was col-
lected immediately prior to the first dose, with further samples collected at
five out of 12 possible times (0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0,
6.0, and 7.8 h) using a balanced randomization schedule. A similar ran-
domization schedule was used to select the final 5 collection times from
1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 8.0, 9.0, 10.0, and 11.8 h after the third dose.
In study 2, children were also randomized using a computer-gener-
ated schedule to receive ArTiMist or i.v. quinine. ArTiMist was adminis-
tered at a dose of 3.0mg/kg (to the nearest 6.0mg) using 6.0-mg/actuation
delivery devices at 0, 8, 24, 36, 48, and 60 h. Following the initial six doses,
patients could, at the discretion of the local investigator, receive a further
four daily doses of 3 mg/kg of ArTiMist to complete a 7-day treatment
course or be changed to another suitable treatment, typically artemisinin
combination therapy (ACT), in accordance with the respective national
treatment guidelines. A sparse sampling protocol was used. All patients
had a baseline blood sample followed by (i) three samples selected at
random from 0.25, 0.5, 0.75, 1.0, 1.5, or 2.0 h after the first dose, (ii) five
samples selected at random from 0.5, 0.75, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 7.0,
7.5, 8.0, or 11.5 h after the third dose, and (iii) immediately before and 1.5
h after the sixth dose in all patients. Amaximumof 10 blood samples were
drawn from any child (total volume,20ml). In both studies 1 and 2, the
weight of the delivery device was measured before and after each dose so
that the actual dose could be calculated.
Drug assays. Plasma artemether and DHA concentrations were mea-
sured using a high-performance liquid chromatography-tandem mass
spectrometric method based on that of Shi et al. (15), described in the
accompanying paper (12). The calibration curves were linear for both
artemether and DHA from 2 to 200 ng/ml (r 0.995, P 0.0001), with
between-day and within-day precision of 11% for both analytes at the
limit of quantification (LOQ), as well as at low,medium, and high plasma
concentrations. The LOQwas 2 ng/ml (signal-to-noise ratio,5), and the
limit of detection was 1 ng/ml (signal-to-noise ratio, 3) for both arte-
mether and DHA.
Pharmacokinetic modeling. Loge plasma concentration-time data
sets for artemether and DHA were analyzed by nonlinear mixed-effects
modeling using NONMEM (version 7.2.0; Icon Development Solutions,
Ellicott City, MD, USA) with an Intel Visual Fortran 10.0 compiler, as
described previously (12). The first-order conditional estimation with
interaction (FOCE-I) estimationmethod was used. The minimum objec-
tive function value (OFV) and visual predictive checks was used to choose
suitable models during the model-building process. A P value of 0.05
was set as the significance level for a comparison of the nested models.
Allometric scaling was employed a priori, with the volume terms multi-
plied by (body weight [BW]/70)1.0 and clearance terms by (BW/70)0.75
(16). Residual variability (RV) was estimated as the additive error for the
log-transformed data. Secondary pharmacokinetic parameters, including
area under the concentration-time curve from time zero to infinity
(AUC0–) and the elimination half-life (t1/2), for the participants were
obtained from post hoc Bayesian predictions in NONMEMusing the final
model parameters. The basemodels were parameterized using ka (absorp-
tion rate constant), Vc (central volume of distribution), CL (clearance),
and Vp and Q (peripheral volumes of distribution[s] and their respective
intercompartmental clearance[s]). The data from the two studies were
pooled for pharmacokinetic modeling.
Initially, only the artemether data set was used, with one-, two- and
three-compartment models (ADVAN2, -4, and -12, respectively) being
tested. As a double peak was noted in many of the individual time-con-
centration curves for ArTiMist, as was seen in a study conducted in
healthy volunteers (12), a number of absorption models were tested, and
once a suitable structural model for artemether had been established, the
plasma DHA concentration data were included. Custom general linear
disposition models were constructed using ADVAN5. The modeling of
artemether and DHA was performed simultaneously. To allow identifi-
ability in the parent-metabolite model, the complete conversion of arte-
mether to DHA was assumed. Thus, all artemether parameters were rela-
tive to bioavailability (F), while all DHA parameters were relative to F
metabolic conversion (F*). One and two additional compartments were
tested for DHA, as well as models estimating the degree of first-pass (FP)
metabolism of artemether to DHA. Once the structure of the models was
established, interindividual variability (IIV) and interoccasion variability
(IOV), as well as correlations between the IIV terms, were evaluated for
each suitable parameter and included where supported by the data. IIV
was modeled exponentially for all parameters, with the exception of the
degree of FP metabolism, for which a probit distribution (with variability
fixed to 1) was utilized to ensure estimates between 0 and 1.
The time-dependent kinetics of artemether were assessed using two
different approaches. The first assumed that the CL of artemether in-
creased with subsequent doses, an approach used previously for children
with malaria treated with artemether-lumefantrine (5, 17). The second
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approach considered the time-dependent kinetics to be attributable to an
increase in the FP metabolism of artemether. As previously noted (18),
this may be attributable to the autoinduction of enzymatic activity. For
both approaches, a different value was estimated for each day of dosing.
For the FP approach, models incorporating FP metabolism for both ab-
sorption phases and for the second phase only were tested.
Potential covariate relationships were investigated first by an inspec-
tion of individual parameter versus covariate plots and using the general-
ized additive model within Xpose (19). The identified relationships were
then tested within NONMEM using a stepwise forward and backwards
approach (P 0.05 for forward steps and P 0.01 for backwards steps).
The tested covariates were sex, age, fever on admission, log10 (baseline
parasitemia), severe versus uncomplicated malaria, vomiting docu-
mented on admission, and Blantyre coma score. The effect size (%) of the
categorical data was assessed, while both linear and power relationships
were evaluated for continuous covariates. The following equations were
used: for effect size:
Individual parameter value population average
 1 effect parameter covariate value (1)
for linear relationships:
Individual parameter value population average
 1 effect individual covariate valuemedian covariate value  (2)
and for power relationships:
Individual parameter value population average
  individual covariate valuemedian covariate value effect parameter (3)
For the model evaluation, plots of observed versus individual- and popu-
lation-predicted values, as well as time versus weighted residuals (WRES),
were assessed. A bootstrap using Perl speaks NONMEM (PSN) with 200
samples was performed, and the parameters derived from this analysis
were summarized as the median and 2.5th and 97.5th percentiles (95%
empirical confidence interval [CI]) to facilitate an evaluation of the final
model parameter estimates. In addition, prediction-corrected visual pre-
dictive checks (pcVPCs) were performed with 1,000 data sets simulated
from the final models. The observed 10th, 50th, and 90th percentiles were
plotted with their respective simulated 95% CIs to assess the predictive
performance of the model and to evaluate anymajor bias. The VPCs were
plotted against the time from the last dose and against the time from the
first dose. Shrinkage of the population variability parameters and residual
variability were incorporated as measures to help determine whether the
models were overparameterized and to determine the reliability of the
diagnostic plots (20).
Simulation study. Using the final model, the concentration-time
curves for artemether and DHA after ArTiMist dosing were simulated for
1,000 children based on the sample studied. The same simulated popula-
tionwas also used to obtain concentration-time curves for artemether and
DHA after the recommended artemether-lumefantrine dosing using a
population pharmacokinetic model previously reported for children (5).
The AUC contribution of the first dose was calculated using standard
pharmacokinetic formulae.
Statistical analysis. Statistical analysis was performed using R version
2.14.2 (R Foundation for Statistical Computing, Vienna, Austria). Two-
sample comparisons for nonnormally distributed variables were assessed
by the Mann-Whitney U test. Unless otherwise stated, all P values are
two-tailed and unadjusted for multiple comparisons.
RESULTS
Patient characteristics. The baseline characteristics of the partic-
ipants in each study are summarized in Table 1. There were 16
patients recruited to study 1 who received ArTiMist, but one was
withdrawn after the second dose due to a protocol violation (in-
correct drug storage). In study 2, a total of 76 patients were allo-
cated to ArTiMist from the three sites (27, 25, and 24 children
from Rwanda, Ghana, and Burkina Faso, respectively). All pa-
tients responded toArTiMist with prompt parasite clearance (me-
dian parasite clearance time in both studies, 24 h), and there were
no treatment-related serious adverse events (data not shown).
Pharmacokinetic modeling. There were 824 and 788 individ-
ual plasma concentrations for artemether and DHA, respectively,
and 4 (0.5%) and 72 (9.1%) of the artemether and DHA concen-
trations, respectively, were below the limit of quantification
(BLQ). Given that BLQ data comprised 10% of the total data,
these were excluded from the analysis using method M1 for deal-
ing with BLQ data (21).
The structural model derived for the artemether andDHA dis-
positions was the same as that in used in the study with healthy
volunteers (12). A two-compartment model for artemether was
most appropriate, with no benefit obtained from additional com-
TABLE 1 Baseline characteristics of participants in studies 1 and 2
Characteristic Study 1 Study 2 Combined
n 15 76 91
Wt (median [IQR]) (kg)a 10.3 (9.8–14.0) 12.0 (10.0–13.7) 12.0 (10.0–13.8)
Age (median [IQR]) (yr) 3.4 (1.6–4.0) 2.7 (1.8–3.5) 2.8 (1.8–3.5)
Male (no. [%]) 7 (44) 36 (47) 43 (47)
Ht (median [IQR]) (cm) 82 (75–92) 87 (81–93) 87 (79–93)
Baseline parasitemia (median [IQR]) (no.
of parasites/l)
19,660 (13,710–26,310) 52,775 (20,047–193,669) 41,383 (16,805–141,834)
Admission temp (median [IQR]) (°C) 38.1 (37.6–38.9) 38.7 (37.8–39.5) 38.7 (37.8–39.4)
Severe malaria (no. [%]) 10 (63) 48 (63) 58 (63)
Vomiting at admission (no. [%]) 2 (13) 46 (61) 48 (52)
Blantyre coma score (no. [%]) of:
1 0 (0) 2 (3) 2 (2)
2 0 (0) 0 (0) 0 (0)
3 1 (6) 7 (9) 8 (9)
4 2 (13) 7 (9) 9 (10)
5 13 (81) 60 (79) 73 (79)
a IQR, interquartile range.
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partments (P  0.05). A two-phase absorption was superior to
single-phase absorption (P 0.001). This was represented by two
separate lag times (LAG1 and LAG2), followed by first-order ab-
sorption with two separate absorption rates (ka1 and ka2). The
ratio of the fraction of the dose absorbedwith the first phase versus
the second phase (RATIO) was estimated within NONMEM. The
second phase of ArTiMist absorption occurred slightly1 h after
drug administration. A model estimating a bolus input was also
tested; however, this was estimated at 1% of the total dose and
did not improve the overall fit. A single additional compartment
was suitable for characterizing the disposition of DHA. LAG1 was
fixed to a value obtained in the final artemether-only model for
the simultaneous modeling of both the parent drug and the me-
tabolite to enable successful minimization.
Models with increasing FP metabolism for subsequent doses
were better than those with increasing clearance for subsequent
doses in describing the time-dependent kinetics of artemether. A
model with FP metabolism influencing the second, but not the
first, phase of absorption, as pertains in healthy adult volunteers
(12), resulted in a worse fit of the data.
The population maximum of FP metabolism for the first day
was estimated at 18%, increasing to 84.0% on the second day and
to 96% on the last day of dosing. The ratio of the population
maximum to the populationminimumof FPmetabolismwas 1.5.
IIV was estimable for artemether (ARM) clearance (CLARM),
DHA clearance (CLDHA), and ka1, with values of 33%, 29%, and
121%, respectively. As in the studies using healthy adults (12), IIV
and IOV could not be estimated simultaneously for RATIO, with
the estimate for IOV being much higher (197%), indicating that
most of the variability was between occasions in the same individ-
ual rather than between different individuals. The IOV of relative
bioavailability was high, at 110%. No significant covariate rela-
tionships were identified.
The final model parameter estimates and the bootstrap results
are summarized in Table 2. The bias was10% for all fixed- and
random-model parameters. Figures 1, 2, and 3 show goodness-of-
fit plots and pcVPCs, which demonstrate the reasonable predic-
tive performance of the model. The half-life and AUC0– values
derived from post hoc individual parameters are shown in Table 3.
These are presented along with equivalent post hoc individual pa-
rameters from a previous study in Melanesian children 5 to 10
years old with uncomplicated malaria who were treated with con-
ventional artemether-lumefantrine tablets (5). The study with
Melanesian children was selected for comparison with the present
TABLE 2 Final population pharmacokinetic variable estimates and bootstrap results of artemether and DHA for study 1a
Parameterb Mean RSE%c Bootstrap (median [95% CI])
Objective function value 1,458.776 1,409.466 (1,249.640–1,596.160)
Structural model parameters
ka1 (/h) 4.15 30 4.01 (1.25–12.5)
ka2 (/h) 0.81 15 0.80 (0.52–1.19)
LAG1 (h) 0.20 6 0.20 (0.14–0.23)
LAG2 (h) 1.24 9 1.24 (0.98–1.40)
RATIO 0.82 29 0.80 (0.44–2.28)
CL/FARM (liters/h/70 kg) 112 9 111 (93.4–136)
Vc/FARM (liters/70 kg) 318 13 319 (216–425)
Q/FARM (liters/h/70 kg) 45.0 16 46.2 (34.1–66.8)
Vp/FARM (liters/70 kg) 1,347 30 1,345 (828–3,404)
CL/F*DHA (liters/h/70 kg) 336 10 342 (270–424)
V/F*DHA (liters/70 kg) 779 15 801 (502–1,017)
FPmax, day1 (%) 0.178 17 0.169 (0.112–0.227)
FPmax, day2 (%) 0.840 8 0.799 (0.681–0.901)
FPmax, day3 (%) 0.959 5 0.935 (0.803–0.990)
FPmax-to-FPmin ratio 1.50 17 1.37 (1.01–1.98)
Variability model parameters (shrinkage %)
IIV in CL/FARM 33 (27) 22 33 (17–53)
IIV in CL/F*DHA 29 (36) 25 29 (12–43)
IIV in ka1 121 (14) 14 121 (79–152)
r(CL/FARM, CL/F*DHA) 0.620 58 0.656 (0.395–0.981)
IOV in F 109 (16, 22, 36, 22) 10 108 (90–132)
IOV in RATIO 197 (33, 21) 13 195 (154–235)
RV for artemether 56 (21) 6 55 (51–62)
RV for DH 83 (11) 4 83 (76–89)
a Fixed in final model; RSE% and 95% CI are from earlier modeling.
b ka1, absorption rate constant for first absorption phase of ArTiMist; ka2, absorption rate constant for second absorption phase of ArTiMist; LAG1, lag time for first absorption
phase of ArTiMist; LAG2, lag time for second absorption phase of ArTiMist; RATIO, ratio between the first and second absorption phases of ArTiMist; CL/FARM, artemether
clearance; Vc/FARM, artemether central volume of distribution; Q/FARM, artemether intercompartmental clearance; Vp/FARM, artemether first peripheral volume of distribution;
CL/F*DHA, DHA clearance; Vc/F*DHA, DHA central volume of distribution; FPmax, day1, FPmax, day2, and FPmax, day3, population maximum first-pass metabolism on days 1, 2, and 3,
respectively; FPmax-to-FPmin ratio, the ratio of the population maximum to the population minimum of FP; r, correlation coefficient; FARM, relative bioavailability of artemether;
F*DHA, FARMmetabolic conversion of artemether to DHA; IOV, interoccasion variability; IIV, interindividual variability; RV, residual variability. IOV and IIV are presented as
100% the square root of the variability estimate.
c RSE, relative standard error.
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study because (i) individual patient data were available for that
study, (ii) as in the present study, blood sampling in that study
included time points beyond those associated with trough con-
centrations, the lack of which has been a limitation of previous
studies (17), (iii) a comparison with pediatric studies of artesu-
nate, whether given parenterally or rectally, would be problematic
given that it is a different artemisinin derivativewith distinct phar-
macologic properties, (iv) i.m. artemether has quite different
pharmacological properties from those of orally administered
artemether, and (v) a proportion of the children in the present
study did not fulfill the WHO criteria for severe malaria and
would have been suitable for oral artemether-lumefantrine were it
FIG 1 Goodness-of-fit plots for artemether. The observed plasma concentration has been plotted against population-predicted (upper left) and individual-
predicted (upper right) plasma concentrations, and conditional weighted residuals against time (lower left) and population-predicted plasma concentrations
(lower right). The solid lines in the upper two graphs represent the lines of identity and the dashed lines are the least-squares regression lines.
FIG 2 Goodness-of-fit plots for dihydroartemisinin. The observed plasma concentration has been plotted against population-predicted (upper left) and
individual-predicted (upper right) plasma concentrations, and conditional weighted residuals against time (lower left) and population-predicted plasma
concentrations (lower right). The solid lines in the upper two graphs represent the lines of identity and the dashed lines are the least-squares regression lines.
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not for gastrointestinal symptoms and/or a refusal to take the
tablets.
Between the two studies, there were significant differences in
t1/2 values, corresponding to the difference in weights and ages
between the subjects of the present and Melanesian studies (12.0
versus 19.0 kg and 2.8 versus 7.7 years, respectively; P 0.001 in
each case). There was no significant difference in the dose 1, dose
6, and total AUC0– of artemether or DHA or in the total DHA-
to-artemether ratios. However, the children in the present study
received a higher dose of 2.9 mg/kg versus 1.9 mg/kg in the previ-
ous study (P 0.001). The distribution and terminal t1/2 for arte-
mether were 0.84 and 18 h, respectively, and the elimination t1/2
for DHA was 0.99 h.
The results of the simulation study are presented in Fig. 4 as
box-and-whisker plots demonstrating the 90% prediction inter-
vals (PI) of the artemether, DHA, and combined AUCs after the
first dose of ArTiMist and artemether-lumefantrine. Both demon-
strate wide prediction intervals due to the large variability in the
bioavailability of artemether in the population pharmacokinetic
models. The median (90% PI) combined AUCs for ArTiMist and
artemether-lumefantrine were 1,380 (201 to 8,689) g · h/liter
and 1,039 (219 to 5,390) g · h/liter, respectively.
DISCUSSION
The present data show that ArTiMist given at a dose of 3.0 mg/kg
twice daily for 3 days to young African children who have severe
malaria or who are unable to tolerate conventional oral therapy is
promptly and adequately absorbed, regardless of the indices of
severity, including consciousness level and even in patients with a
history of vomiting at presentation. As in healthy adult volunteers
FIG 3 Prediction-corrected visual predictive check for plasma artemether (A) and dihydroartemisinin (DHA) (B) (in micrograms per liter on a log10 scale)
plotted against time after the last dose, with observed 50th (solid line) and 10th and 90th (dotted lines) percentiles within their simulated 95% CI (gray shaded
areas) overlying the data points (Œ).
TABLE 3 Derived secondary pharmacokinetic parameters from post hoc individual parameters for the present studies compared with those from a
previous study (5) of artemether-lumefantrine in Melanesian children 5 to 10 years old with uncomplicated malaria
Parametera Present studies Prior oral artemether study P value
Artemether
t1/2 (h) 0.841 (0.747–0.926) 0.62 (0.60–0.64)
b 0.001
t1/2	 (h) 18.3 (17.7–19.9) 16.4 (15.7–16.8)
b 0.001
AUC0– (g · h/liter)
Dose 1 894 (473–1,420) 983 (371–1,770) 0.88
Dose 6 232 (147–380) 164 (145–254) 0.15
Total 3,403 (2,471–4,771) 3,063 (2,358–4,514) 0.63
Total normalized to dose 1.18 (0.85–1.64) 1.63 (1.26–2.44) 0.001
Dihydroartemisinin
t1/2 (h) 0.987 (0.859–1.11) 0.80 (0.76–0.82) 0.001
AUC0– (g · h/liter)
Dose 1 355 (206–626) 362 (136–652) 0.77
Dose 6 448 (277–690) 311 (214–440) 0.09
Total 2,958 (2,146–4,278) 2,839 (1,812–3,488) 0.42
Total normalized to dose 1.04 (0.71–1.42) 1.52 (0.98–1.89) 0.052
Dihydroartemisinin-to-artemether ratio
Dose 1 0.42 (0.38–0.46) 0.37 (0.37–0.37) 0.001
Dose 6 1.74 (1.57–2.01) 1.86 (0.92–2.68) 0.97
Total 0.85 (0.74–1.04) 0.93 (0.59–0.94) 0.46
a Data are presented as the median (interquartile range). t1/2, first half-life; t1/2	, second half-life; AUC0–, area under the concentration-time curve from time 0 to infinity.
b For the first dose.
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(12), there is a biphasic absorption of the drug. However, in con-
trast to our adult data suggesting the avoidance of FP metabolism
during the first phase, there was model-derived evidence of FP
metabolism in both absorption phases in children with malaria.
These data suggest that the amount of artemether absorbed di-
rectly through the oral mucosa in this clinical setting is less than
that in healthy volunteers. Previous models of the time-dependent
pharmacokinetics of artemether have assumed that declining plasma
concentrations reflect increasing drugCL (5, 17).However, the pres-
ent study, utilizing a greater number of plasma concentration-time
coordinates across doses and absorption phases offers support for a
reduction in F through increased FPmetabolism via the induction of
enzymatic activity in the liver and intestines (18, 22).
Pharmacokinetic studies with intensive sampling schedules are
challenging in small children because of the relatively large volumeof
blood thatmight need to be taken and the difficulty in obtaining, and
the discomfort associated with, venous access and/or repeated vene-
sections (23). The use of sparse sampling and a populationmodeling
approach is a better alternative. We employed this approach in the
present study and found that the final structural models characteriz-
ing sublingual artemether and DHA dispositions in our young Afri-
can children were similar to those in healthy adult volunteers who
underwent intensive postdose blood sampling (12). This provides
evidence supporting the validity of the pharmacokinetic parameters
derived in the present study.
The only difference in the ArTiMist dispositions between the
present studies and our investigations in healthy adult volunteers
(12) related to the first phase of absorption. There was evidence of
FPmetabolism during the first phase of absorption in the children
with malaria, while the ka1 in the pediatric study was faster than
that in the adults (4.15/h versus 1.46/h, respectively) (12). This
suggests that the retention time in the sublingual space is longer in
healthy adults than in sick young children; also, in the young chil-
dren, some artemether was swallowed soon after administration
and absorbed through the upper gastrointestinal tract into the
portal venous system rather than exhibiting the more substantial
sublingual absorption as seen in the adult volunteers. There was
no requirement to restrict fluids or food after ArTiMist dosing in
the present study. Since rehydration is an important part of the
management of acute malaria in children, it is possible that a sig-
nificant proportion of the children were given water after dosing,
and this promptly transferred the drug into the stomach. The
slower second absorption phase paralleled that in adults and may
represent drug in the buccal cavity that enters the stomach more
slowly in swallowed saliva.
Although there are age-related differences in the factors affect-
ing sublingual drug absorption, this route of delivery is used for
the administration of analgesics, immunotherapy, and other
treatments in children (24).However, of potential relevance to the
present data is the observation that there is abnormal sublingual
microcirculatory density and function in pediatric sepsis (25, 26),
which may be exacerbated by the microvascular sequestration of
P. falciparum (27) inmalaria. These factorsmight have attenuated
the buccal absorption of ArTiMist in our children but may not
have been influential in the upper small intestine.
Young children between 1 and 6 years of age, such as those who
formed the majority of patients in the present studies, may have
increased body weight-normalized plasma drug clearance and a
need for higher milligram-per-kilogram doses than those in older
children and adults (28). Thus, although ArTiMist has increased
bioavailability relative to that of tablets containing the same dose
in healthy adults (12), repeated 3.0-mg/kg ArTiMist doses in the
African children in the present study achieved a similar drug ex-
posure (AUC0–) to only 1.7mg/kg/dose by artemether-lumefan-
trine tablets in older children from Papua New Guinea (PNG) (5)
(see Table 3). This finding emphasizes the value of age-specific
pharmacokinetic studies as part of drug development.
Themedian and range of artemether andDHAAUC0– values
across the six doses (as evidenced by the interquartile ranges in
Table 3) were generally similar in African and PNG children, al-
beit after different doses. The simulation study produced a similar
result. Importantly, the lower bounds of the 90% PI are almost
identical, indicating that there is no increased risk of underdosing
artemether with the current ArTiMist regimen compared to the
recommendeddoses of artemether-lumefantrine tablets. The high
degree of between-subject variability parallels that with intramus-
cular artemether (8, 9). However, sublingual/oral dosing has the
added benefit that the swallowed fractionmay undergo FPmetab-
olism of artemether to DHA, with higher relative amounts of the
more potent metabolite being present (29).
Given the WHO recommendations regarding the need for ar-
temisinin drugs to be administered in combination with a longer
half-life partner (such as lumefantrine), except in situations in
which initial oral therapy cannot be given safely and reliably (30),
ArTiMist is likely to have application as one- or two-dose prere-
ferral treatment, as sick children are transferred for parenteral
artemisinin therapy or oral ACT. In view of potential pharmaco-
kinetic (8), cultural (31), and efficacy (11) concerns regarding
artesunate suppositories in this situation, ArTiMist appears to be a
valuable alternative. The present study is the first clinical evalua-
tion of this novel antimalarial treatment strategy, and the popula-
tion models developed from the data have provided initial phar-
macokinetic insights. Further studies should examine in greater
detail the effects of factors, such as the ingestion of oral fluids and
food, on ArTiMist disposition in sick children with malaria, as
well as compare the pharmacokinetics and efficacy of sublingual
artemether administration to those after parenteral administra-
tion of artemisinin derivatives in similar groups of patients.
FIG 4 Results of the simulation study presented as box-and-whisker plots
demonstrating the 90% prediction intervals for artemether AUCs, dihydroar-
temisinin (DHA) AUCs, and combined AUCs after the first doses of ArTiMist
and artemether-lumefantrine tablets. The horizontal line in each box repre-
sents themedian and the box indicates the interquartile rangewithin each 95%
prediction interval (vertical lines).
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